• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
The Impact Investor | ESG Investing Blog

The Impact Investor | ESG Investing Blog

Investing for financial return is only part of the equation.

  • ESG Investment Products
    • Best Impact Investing Apps
    • Best ESG Funds
    • Best Socially Responsible Mutual Funds
    • Best BlackRock SRI Funds
    • Best Vanguard ESG Funds
    • Best Sustainable Robo-Advisors
  • ESG Education
    • How to Build a Socially Responsible IRA Portfolio
    • ESG Principles
    • ESG Shareholder Activism
    • Why You Need ESG Investing
    • ESG Investing Trends
    • Social Impact Examples
    • Impact Investing Examples
  • Careers in ESG
    • Best ESG Jobs
    • Best Corporate Responsibility Jobs
    • Environmental Justice Jobs
JOIN

Merck & Co., Inc. ESG Profile (MRK): Is It Sustainable?

Updated on April 20, 2022

Our posts may contain links from our affiliate partners. This supports helps support the site as we donate 10% of all profits to sustainability organizations that align with our values. However, this does not influence our opinions or ratings. Please read our Terms and Conditions for more information.

Our (MRK) ESG Review

 Logo
$105.85
SymbolMRK
Price$105.85
52 Week High šŸ“ˆ$115.49
52 Week Low šŸ“‰$78.77
Earnings Per Share šŸ’µ5.71
Dividend Yield šŸ”2.651297

Merck & Co., Inc. is one of the largest pharmaceutical companies in the world, with a long history of commitment to science and innovation. The company has a strong focus on research and development, and has been a pioneer in many important medical advances, including vaccines for polio, measles, mumps, rubella, varicella (chickenpox), and hepatitis B. Merck also developed the first anti-viral drug, acyclovir, for the treatment of herpes simplex virus infections, and the first approved human papillomavirus vaccine.

Merck’s commitment to responsible business practices extends beyond its research and development work. The company has been a leader in promoting access to medicines in developing countries, and was the first pharmaceutical company to sign the United Nations Global Compact. Merck has also been recognized for its leadership in environmental sustainability, including being named to the Dow Jones Sustainability World Index for 15 consecutive years.

Merck’s ESG rating is strong, with the company receiving top marks for its disclosure and performance in several key areas. The company is rated AAA by MSCI, the highest possible rating, for its environmental and social practices. Merck is also a member of the Dow Jones Sustainability World Index, and has been recognized as one of the world’s most sustainable companies by Corporate Knights. The company’s strong ESG rating is reflective of its long-standing commitment to responsible business practices. Merck has been a leader in promoting access to medicines in developing countries, and was the first pharmaceutical company to sign the United Nations Global Compact.

What We Like
  • Diversified global health care company with strong research & development capabilities

  • Leading position in the vaccine market with blockbuster products such as Gardasil 9

  • A strong commitment to environmental, social, and governance (ESG) issues

What We Don't Like
  • The company is highly dependent on patented drugs, which are subject to generic competition

  • Merck has been involved in several major litigation cases in recent years

MRK ESG Summary

This is a summary of 's ESG scores from Sustainalytics, MSCI, and ESG Enterprise.

ESG Rating Agency Score or Rating
Sustainalytics 64
MSCI
ESG Enterprise BBB

MRK
Sector: Healthcare
Industry: Drug Manufacturers—General
Employees: 67,000
Business Description

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women’s health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Company
ExchangeNYQ
Address2000 Galloping Hill Road
Go to top

Popular ESG Stocks

Popular ESG Stocks
StockMarketcapIndustryPriceChange %52 Week RangeChart (24H)EPSDividend Yield
NVDA
NVIDIA Corporation
NVDA
645.43BSemiconductors$259.000.68%
2.350.06%
MSFT
Microsoft Corporation
MSFT
2.03TSoftware—Infrastructure$272.232.58%
9.000.93%
BBY
Best Buy Co., Inc.
BBY
17.04BSpecialty Retail$78.131.82%
6.294.59%
ADBE
Adobe Inc.
ADBE
166.41BSoftware—Infrastructure$362.881.32%
10.270.00%
CRM
Salesforce, Inc.
CRM
185.25BSoftware—Application$185.250.22%
0.200.00%
INTU
Intuit Inc.
INTU
116.79BSoftware—Application$411.840.45%
6.870.71%
POOL
Pool Corporation
POOL
13.71BIndustrial Distribution$342.950.33%
18.701.11%
PYPL
PayPal Holdings, Inc.
PYPL
82.83BCredit Services$73.210.30%
2.090.00%
GOOGL
Alphabet Inc.
GOOGL
1.30TInternet Content & Information$101.220.39%
4.540.00%
FSLR
First Solar, Inc.
FSLR
21.82BSolar$204.682.53%
0.410.00%

FAQ

How much is (MRK) stock?

The current stock price of (MRK) is $105.85.

What is (MRK)'s ESG Score?

(MRK) has an ESG score of 64, BBB, and as rated from Sustainalytics, ESG Enterprise, and MSCI, respectively.

Stocks

$105.85
Open $104.82
High $106.91
Close $104.10
Low $104.82
Volume 12,841,987

MRK ESG Scores 🌱
Sustainalytics 64
MSCI
ESG Enterprise BBB

Buy for $105.85

Popular ESG Stocks
Nvidia LogoNVDA
Microsoft LogoMSFT
Best Buy LogoBBY
Adobe LogoADBE
Salesforce LogoCRM
Polar BearPolar Bear on Ice on Ice

Future Generations Will Thank You

Join the newsletter and learn how you can make a invest for financial return and make a positive impact.

JOIN NOW

Footer

About

The Impact Investor is a blog focused on helping retail investors find ESG, socially responsible, and impact investment opportunities through our expert insights, tips, and blog posts.

Resources

  • Best ESG Jobs
  • Best ESG Stocks
  • Best EV Battery Stocks
  • Best ESG Analysis Tools
  • How to Finance Solar Panels

Tools

  • Tesla Charging Calculator
  • Solar Loan Calculator
  • PACE Loan Calculator
  • Electric Bill Calculator

Products

  • Best Investing Apps
  • Best Robo-Advisors
  • Best ESG Funds
  • Vanguard ESG Funds
  • Best Green Credit Cards

Marketplace

  • Community Solar Providers
  • Best Car Insurance for EVs
  • Best Home Solar Systems
  • Best Green Auto Loans

Contact

  • About
  • Contact Us
  • Privacy Policy
  • Disclaimer
  • Facebook
  • Instagram
  • Twitter
  • YouTube

Copyright © 2023 The Impact Investor